Danaher Corporation (DHR) Business Profile

What it does

Danaher is a global science and technology company focused on improving human health. It operates more than 15 businesses in three segments: Biotechnology, Life Sciences and Diagnostics. Its businesses sell equipment, consumables, software and services, and many sales recur as customers repeatedly buy tests, reagents, filters, media, other consumables and service.

The Biotechnology segment helps drugmakers and biotechnology companies research, develop and manufacture biological medicines. Its tools support workflows from early process development to commercial manufacturing, including cell culture media, filtration, chromatography, aseptic filling, single-use hardware, automation and manufacturing-suite design.

Life Sciences supplies instruments and consumables used to study DNA, RNA, proteins, metabolites and cells. Researchers use these products in drug discovery, clinical development, gene editing, academic research, quality control and industrial applications. The segment also sells filtration products for applications ranging from microelectronics and aircraft to food and beverage production.

Diagnostics sells clinical instruments, tests, consumables, software and services to help healthcare professionals diagnose disease, monitor patients and make treatment decisions. Its molecular systems automate DNA-based testing, while its clinical businesses serve laboratory, acute-care and pathology workflows.

Rainer M. Blair has served as President and Chief Executive Officer since September 2020. Danaher was founded in 1981 and is headquartered in Washington, D.C.

How it makes money

Danaher earns revenue through three operating segments. Biotechnology sells equipment, consumables, software and services for the development and manufacture of biological medicines. Its bioprocessing business supplies products and services across customers’ workflows, from process development through large-scale commercial manufacturing. Its discovery and medical business provides laboratory filtration, separation, purification, assay-development and healthcare-filtration products.

Life Sciences earns revenue from instruments, software, reagents, antibodies, assays, custom DNA and RNA products, filtration consumables and related services. Its instrument businesses include lab automation, flow cytometry, mass spectrometry and microscopy. Its consumables businesses supply products used in genomics, proteomics, research, diagnostics and cell and gene therapy development.

Diagnostics sells molecular testing systems and related consumables, as well as clinical laboratory, acute-care and pathology instruments, software, tests and services. Molecular diagnostic systems automate sample preparation, DNA amplification and detection; clinical products help laboratories and healthcare professionals diagnose, monitor and manage disease.

Recurring sales were $20.1 billion in FY2025, representing 81.9% of revenue. This category includes products typically bought repeatedly, while equipment and other products typically sold less frequently are nonrecurring. The company generally sells through direct sales teams, supplemented by independent distributors.

FY2025 recurring revenue was $20.1 billion; Q3 2026 sales were $6.6 billion. Management said on the call that core revenue excluding respiratory revenue grew 5.5% in Q3 2026, while respiratory revenue was an approximately 250 basis point headwind.

Customers and how it sells

Danaher’s customers include pharmaceutical and biopharmaceutical companies, biotechnology companies, contract manufacturers, hospitals, physicians’ offices, reference laboratories, pathology laboratories, academic and translational research institutions, universities, medical schools and industrial manufacturers. In diagnostics, customers use its products to test patient samples, support acute care, diagnose disease, guide treatment and manage chronic conditions. In life sciences and biotechnology, customers use its products in research, drug development, laboratory workflows and therapeutic manufacturing.

The company primarily uses a direct sales model, though its businesses also sell through independent distributors. In lower-volume countries, it generally sells through representatives and distributors. Customer selection factors differ by product line but include quality, reliability, performance, speed, ease of use, technical expertise, service and support, product breadth and total cost of ownership.

North America generated $10.4 billion of FY2025 revenue, or 42.2% of revenue. High-growth markets generated $7.0 billion, or 28.6%, and Western Europe generated $5.9 billion, or 24.2%. The company defines high-growth markets as Eastern Europe, the Middle East, Africa, Latin America including Mexico, and Asia excluding Japan, Australia and New Zealand. Its facilities are located in approximately 50 countries, and its products and services are available worldwide.

Suppliers and costs

Danaher manufactures products in North America, Europe and Asia, with Diagnostics also manufacturing in Australia. Its operations use metallic and electronic components, chemistries, OEM products, plastics and other petroleum-based materials. Oil and gas prices also affect freight, utilities and the cost of purchased materials.

The company buys materials from a large number of global sources, and no single supplier is material to the company. However, particular components may have only one readily available supplier, or a limited number of suppliers, because they require specific technical, regulatory or other qualifications. Danaher uses safety stock, alternative materials and qualification of multiple sources to address potential disruption.

Tariffs and trade protection measures can affect component availability and cost. The company incurred incremental tariff costs of less than $300 million in 2025 and largely offset the operating-profit effect through manufacturing-footprint changes, supply-chain adjustments, surcharges, productivity actions and cost savings. The company states that additional enacted or threatened tariffs could adversely affect revenue and profitability.

Competitive position

Danaher competes in biotechnology, life sciences and diagnostics markets that it describes as highly competitive. It faces regional competitors, companies specialized in particular markets, large companies and divisions of large companies with sales, marketing, research and financial resources. Competition has increased in some served markets because of well-resourced entrants, competitors operating from low-cost manufacturing locations, emerging technologies and consolidation.

The company does not identify competitors that offer its complete range of products and services or serve all of its markets. It states that competitive position cannot be determined accurately across the company or by segment because competitors’ product lines and markets differ.

Competitive factors include price, quality and safety, performance, delivery speed, application expertise, service and support, technology and innovation, distribution, breadth of product, service and software offerings, and brand recognition. Biotechnology and Life Sciences customers also consider technical expertise, productivity, sensitivity and product reliability. Diagnostics customers consider test scope, accuracy, speed, ease of use and total cost of ownership.

Danaher owns patents, trademarks, copyrights, trade secrets and licenses, although it does not consider any individual intellectual-property asset or related group of assets material to a segment or the company as a whole. It conducts research and development internally and through licensed or acquired technology, and works with research institutions, universities and clinicians to develop, evaluate and clinically test products.

No competitors are named in the available company information.

Growth opportunities

Danaher’s long-term growth approach combines investment in existing businesses, research and development, acquisitions, investments and strategic partnerships. The company seeks to deepen positions in biotechnology, life sciences and diagnostics and to connect capabilities across its operating companies. It also states that future growth depends partly on developing products and sales models for high-growth markets.

In FY2025, Biotechnology revenue was $7.3 billion, up 7.90%; Diagnostics revenue was $9.9 billion, up 1.57%; and Life Sciences revenue was $7.3 billion, up 0.07%. Management said on the call that Q3 2026 core revenue excluding respiratory revenue rose 5.5%, with Biotechnology, Life Sciences and Diagnostics each growing mid-single digits or better on that basis.

Bioprocessing is a stated growth area. Management said on the call that its bioprocessing order growth was mid-teens in Q3 2026, supported by upstream consumables and reagents, and that the company views the business as capable of sustainable high-single-digit long-term revenue growth. The company identifies monoclonal antibodies, biosimilars, cell therapy, antibody-drug conjugates and other modalities as drivers of biologics manufacturing demand. Management also said that larger reshoring projects are generally expected to affect results from 2028 onward.

Management said on the call that the company is deploying AI across commercial activity, innovation and laboratory workflows. Its Abcam autonomous laboratory combines AI, robotics and technologies from multiple Danaher businesses in a connected design, make and test workflow. Management said the company expects this platform to help researchers move from idea to validated reagent up to eight times faster than existing models.

Structural risks

• Healthcare funding, reimbursement and pricing: Many customers and end users rely on government funding and reimbursement for healthcare products, services and research. Reduced reimbursement, price ceilings or lack of payer coverage can reduce product use, demand and the prices customers will pay.

• Regulation and product authorization: Medical-device and diagnostic products are subject to extensive regulation across development, testing, manufacturing, labeling, marketing, distribution and post-market surveillance. Product changes can require new regulatory clearance or approval.

• Competition and innovation: The company must identify customer needs, respond to competitors’ innovation, obtain intellectual-property rights, commercialize products on time and convince customers to adopt new technologies. It also faces price competition and risk of product commoditization.

• International operations and trade: Global operations expose the company to tariffs, export restrictions, supply interruptions, currency movements, differing payment terms, local product requirements, political and economic changes, data-privacy requirements and changing healthcare policies.

• Acquisitions and debt: Acquired businesses can underperform expectations, be difficult to integrate, fail to produce anticipated savings or synergies, and add liabilities. Acquisitions and investments can also require significant debt and increase interest expense or borrowing costs.

• IT, data and intellectual property: The company relies on IT systems, including systems managed by third parties, to process sensitive business, customer, employee and patient information. Security breaches, data-privacy violations, counterfeiting or difficulty protecting intellectual property could adversely affect the business.

Leadership

Steven M. Rales and Mitchell P. Rales are co-founders and brothers; Steven M. Rales is Chairman of the Board and Mitchell P. Rales is Chairman of the Executive Committee. Both have served on Danaher’s Board of Directors since 1983.

Bottom line

Our reading

Our reading: Danaher is a diversified healthcare-tools business spanning scientific research, biologics manufacturing and clinical diagnostics, with recurring consumables, tests and services forming much of its revenue base. Its operating model combines separately managed businesses with the Danaher Business System, direct customer relationships and global manufacturing. Its results remain exposed to healthcare reimbursement, regulation, trade policy, research funding, product innovation and acquisition integration. Management’s current growth agenda centers on commercial execution, connected workflows, bioprocessing and AI-enabled laboratory automation.